Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
5.74
0.00 (0.00%)
At close: Mar 6, 2026, 4:00 PM EST
5.72
-0.02 (-0.35%)
After-hours: Mar 6, 2026, 7:00 PM EST
Artiva Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Artiva Biotherapeutics stock have an average target of 19.2, with a low estimate of 15 and a high estimate of 23. The average target predicts an increase of 234.49% from the current stock price of 5.74.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 12, 2025.
Analyst Ratings
The average analyst rating for Artiva Biotherapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $15 | Strong Buy | Maintains | $12 → $15 | +161.32% | Nov 12, 2025 |
| Wedbush | Wedbush | Buy Maintains $18 → $23 | Buy | Maintains | $18 → $23 | +300.70% | Oct 17, 2025 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +213.59% | Oct 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +109.06% | Jun 11, 2025 |
| Needham | Needham | Strong Buy Maintains $23 → $18 | Strong Buy | Maintains | $23 → $18 | +213.59% | May 15, 2025 |
Financial Forecast
Revenue This Year
n/a
from 251.00K
Revenue Next Year
n/a
EPS This Year
-3.47
from -5.81
EPS Next Year
-3.41
from -3.47
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.44 | -2.30 | ||||
| Avg | -3.47 | -3.41 | ||||
| Low | -3.43 | -4.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.